Brussels has accused Illumina of using “delay tactics” to prevent a speedy ruling on whether the world’s biggest gene sequencing company should be forced to divest cancer test developer Grail.
It follows repeated claims by Illumina that it is moving as “expeditiously as possible” to resolve litigation linked to its $8bn acquisition of Grail, which is the focus of a bruising proxy battle waged by Carl Icahn, the veteran activist investor.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased